AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS

Rhea-AI Summary

Amgen (NASDAQ: AMGN) has announced a $650 million expansion of its U.S. manufacturing network, focusing on its biologics facility in Juncos, Puerto Rico. The investment will create 750 new jobs, including construction and highly skilled manufacturing positions.

The expansion aims to enhance drug production capacity and integrate advanced technologies. This initiative follows Amgen's substantial investments since 2017, including a $600 million science center in California and manufacturing expansions worth $900 million in Ohio and $1 billion in North Carolina.

The project is supported by tax policies from the Tax Cuts and Jobs Act of 2017 and the One Big Beautiful Bill Act of 2025, reflecting Amgen's $40 billion total investment in U.S. manufacturing and R&D since 2017.

Positive

• Creation of 750 new jobs, including highly skilled manufacturing positions
• Major $650 million investment strengthening U.S. manufacturing capabilities
• Expansion of biologics production capacity in Puerto Rico
• Part of larger investment strategy totaling over $40 billion in U.S. manufacturing and R&D
• Strategic enhancement of global supply chain resilience

Negative

• Significant capital expenditure requiring substantial financial commitment
• Extended timeline for return on investment in manufacturing infrastructure

Insights

Biotech Investment Analyst

Amgen's $650M Puerto Rico expansion strengthens manufacturing capacity, creates 750 jobs, and demonstrates continued U.S. investment commitment.

Amgen's $650 million manufacturing expansion in Puerto Rico represents a strategic strengthening of its production capabilities with material impact on its long-term operations. This investment specifically targets the company's biologics manufacturing facility in Juncos, integrating advanced technologies while creating approximately 750 new jobs, including both construction and specialized manufacturing positions.

This expansion follows a pattern of significant domestic investment by Amgen since the 2017 Tax Cuts and Jobs Act, with over $40 billion allocated to manufacturing and R&D capabilities. The company's recent capital expenditures now total over $3.15 billion when including their $600 million California science center and manufacturing expansions in Ohio ($900 million) and North Carolina ($1 billion).

For investors, this signals Amgen's confidence in future product demand and commitment to supply chain resilience. The focus on biologics manufacturing is particularly notable, as biologics typically command higher margins than small-molecule drugs and face less generic competition due to manufacturing complexity. The Puerto Rico facility expansion leverages the region's established biopharmaceutical expertise while benefiting from favorable tax treatment under recent legislation.

This commitment to U.S. manufacturing aligns with bipartisan political priorities around domestic production of critical medicines. The creation of high-quality jobs and investment in cutting-edge manufacturing technology suggests Amgen is positioning itself for sustained long-term growth rather than simply maximizing short-term returns.

THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly skilled manufacturing jobs. 

"This expansion underscores Amgen's commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain," said Robert A. Bradway, chairman and chief executive officer at Amgen. "By growing our capacity to deliver innovative medicines with cutting edge technology in our manufacturing plants, we will not only better serve patients but also create high-quality jobs that reinforce America's leadership in biotechnology."

"Amgen's multimillion-dollar expansion reflects a bond of mutual loyalty: Amgen's sustained investment and Puerto Rico's skilled, resilient workforce reinforcing each other over time," said Puerto Rico Governor Jenniffer González Colón. "This new expansion not only strengthens U.S. supply chain security through reshoring, it also opens new horizons for our people as we build an innovation ecosystem that positions Puerto Rico as the strongest biopharmaceutical hub in the United States."

"Puerto Rico boasts more than 60 years of expertise and excellence in the biopharmaceutical sector, supported by highly skilled talent and world-class infrastructure," said Sebastián Negrón Reichard, Puerto Rico Secretary of the Department of Economic Development and Commerce. "This investment by Amgen is a testament to how committed we are to advancing a competitive and innovative ecosystem that allows global companies to grow and prosper in Puerto Rico."

Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen's ability to invest domestically in cutting-edge science and manufacturing.

This announcement builds on Amgen's recent investments, including a $600 million science and innovation center in California and manufacturing expansions of $900 million in Ohio and $1 billion in North Carolina, respectively.

About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average^®, and it is also part of the Nasdaq-100 Index^®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. 

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads.

Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT: Amgen, Thousand Oaks
George Shea, 202-531-7364 (media)
Elissa Snook, 609-251-1407 (media)
Adam Elinoff, 805-313-9775 (investors) 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-650m-expansion-of-us-manufacturing-creating-hundreds-of-new-jobs-302567939.html

SOURCE Amgen

FAQ

How much is Amgen investing in its new U.S. manufacturing expansion?

Amgen is investing $650 million in expanding its U.S. manufacturing network, particularly at its biologics facility in Juncos, Puerto Rico.

How many jobs will Amgen's manufacturing expansion create?

The expansion will create 750 new jobs, including both construction roles and highly skilled manufacturing positions.

What is Amgen's total investment in U.S. manufacturing and R&D since 2017?

Amgen has invested over $40 billion in U.S. manufacturing and research & development since the Tax Cuts and Jobs Act of 2017.

Where are Amgen's other recent major investments located?

Amgen's other recent investments include a $600 million science center in California, $900 million manufacturing expansion in Ohio, and $1 billion expansion in North Carolina.

What is the purpose of Amgen's manufacturing expansion in Puerto Rico?

The expansion aims to increase drug production capacity, integrate advanced technologies, strengthen the global supply chain, and create high-quality jobs while reinforcing America's leadership in biotechnology.